Balanced news tone
News Sentiment
EPRX sentiment intelligence
Eupraxia Pharmaceuticals Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
80/100 classification confidence.
directly relevant articles
high-authority source matches
-0.1% over one week, +10.6% over four weeks, trend inactive, and materially above fair value.
Eupraxia Pharmaceuticals (EPRX) reshapes leadership and expands Vancouver-Seattle hubs
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Eupraxia Pharmaceuticals’ First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 May 2026 11:00
- Source
- GlobeNewswire
Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 May 2026 11:00
- Source
- GlobeNewswire
Surgeon-scientist Jeymi Tambiah joins Eupraxia as CMO
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 May 2026 07:00
- Source
- Stock Titan
GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Apr 2026 07:00
- Source
- StockStory
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 18 Mar 2026 07:00
- Source
- Market source
Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 05 Mar 2026 08:00
- Source
- Stocktwits
Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Feb 2026 09:53
- Source
- Kavout | AI
Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook
- Tone
- Positive 82/100
- Event
- Earnings
- Published
- 26 Feb 2026 08:00
- Source
- TIKR.com
Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 25 Feb 2026 08:00
- Source
- TIKR.com
This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Feb 2026 08:00
- Source
- Barron's
Eupraxia Pharmaceuticals Announces Pricing of US$55 Million
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Feb 2026 08:00
- Source
- GlobeNewswire
Biotech Eupraxia plans share sale to fund EoE, Crohn’s trials
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Feb 2026 08:00
- Source
- Stock Titan
Eupraxia Pharmaceuticals Announces Proposed Public Offering
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Feb 2026 08:00
- Source
- GlobeNewswire
Molina Healthcare Stock Craters. Why Its Earnings Outlook Is So Bleak.
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 06 Feb 2026 08:00
- Source
- Barron's
Here's Why We're Not At All Concerned With Eupraxia Pharmaceuticals' (TSE:EPRX) Cash Burn Situation
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 05 Feb 2026 08:00
- Source
- Market source
Eupraxia Pharmaceuticals Inc. (TSE:EPRX) surges 15%; retail investors who own 41% shares profited along with institutions
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 09 Jan 2026 08:00
- Source
- simplywall.st
$80.5M Biotech Funding: Eupraxia Secures Major Capital for Esophagitis Drug Development Through 2028
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Sep 2025 07:00
- Source
- Stock Titan
Eupraxia Pharmac (EPRX) Stock Price, News & Analysis
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Apr 2025 22:29
- Source
- Stock Titan
symbol__ Stock Quote Price and Forecast
- Tone
- Neutral 50/100
- Event
- Guidance
- Published
- 07 Apr 2024 12:04
- Source
- CNN